Iovance Biotherapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $58,555 | $31,106 | $715 | $482 |
Gross Profit | 18,732 | -5,640 | -11,820 | -13,597 |
EBITDA | -89,066 | -91,050 | -107,815 | -108,424 |
EBIT | -101,914 | -117,722 | -118,138 | |
Net Income | -83,541 | -97,101 | -112,976 | -116,379 |
Net Change In Cash | 58,555 | 31,106 | 715 | 482 |
Free Cash Flow | -61,261 | -98,871 | -126,450 | -87,499 |
Cash | 164,186 | 228,752 | 134,187 | 114,888 |
Basic Shares | 303,269 | 284,817 | 266,220 | 255,951 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $1,189 | $238 | $0 | $0 |
Gross Profit | -9,566 | -21,135 | -13,980 | -8,712 |
EBITDA | -427,432 | -377,743 | -328,723 | -250,869 |
EBIT | -460,559 | -398,878 | -342,703 | -259,581 |
Net Income | -444,037 | -389,923 | -327,821 | -257,225 |
Net Change In Cash | 1,189 | 238 | 0 | 0 |
Cost of Revenue | 11,459 | 53,435 | ||
Free Cash Flow | -384,110 | -313,182 | -265,515 | -251,925 |
Cash | 114,888 | 231,731 | 78,229 | 67,329 |
Basic Shares | 235,131 | 159,259 | 153,406 | 138,301 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.28 |
2024-06-30 | -$0.34 |
2024-03-31 | -$0.42 |
2023-12-31 | -$0.45 |
